<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834403</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00011685</org_study_id>
    <nct_id>NCT02834403</nct_id>
  </id_info>
  <brief_title>L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients</brief_title>
  <official_title>Clinical Phase Ib/II Trial of L-NMMA Plus Taxane Chemotherapy in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Methodist Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting&#xD;
      toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with&#xD;
      docetaxel in refractory locally advanced or metastatic triple negative breast cancer&#xD;
      patients. The Phase Ib portion of the study is designed to investigate the combination at two&#xD;
      dose levels of docetaxel (75 and 100 mg/m2) and 7 dose levels of L-NMMA (5, 7.5, 10, 12.5,&#xD;
      15, 17.5, and 20 mg/kg). The starting dose of L-NMMA will be 7.5 mg/kg. In the Phase II&#xD;
      portion of the study, the starting dose will be the RP2D determined in the Phase Ib portion&#xD;
      of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting&#xD;
      toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with&#xD;
      docetaxel in refractory locally advanced or metastatic triple negative breast cancer&#xD;
      patients. The Phase Ib portion of the study is designed to investigate the combination at two&#xD;
      dose levels of docetaxel (75 and 100 mg/m2) and 7 dose levels of L-NMMA (5, 7.5, 10, 12.5,&#xD;
      15, 17.5, and 20 mg/kg). The starting dose of L-NMMA will be 7.5 mg/kg. L-NMMA dose will&#xD;
      escalate/de-escalate based on DLT occurrence. For the 5, 7.5, 10, 12.5, and 15 mg/kg L-NMMA&#xD;
      doses, docetaxel will be administered at 75 mg/m2. For the 17.5 and 20 mg/kg L-NMMA doses,&#xD;
      docetaxel will be administered at 100 mg/m2. In the Phase II portion of the study, the&#xD;
      starting dose will be the RP2D determined in the Phase Ib portion of the study. In the phase&#xD;
      II portion of the study, patients will be treated with L-NMMA and taxane (docetaxel,&#xD;
      paclitaxel, or nab-paclitaxel) per physician's choice. Patients will be treated with L-NMMA&#xD;
      and taxane chemotherapy (docetaxel, paclitaxel, or nab-paclitaxel) per physician's choice.&#xD;
      L-NMMA will be administered on Days 1-5 and taxane chemotherapy on Day 1 Q3W or Day 1 Q1W.&#xD;
      L-NMMA and docetaxel will be administered at the RP2D determined in the phase Ib portion of&#xD;
      the study. Paclitaxel at 175 mg/m2 will be IV infused over 3 hours or 80 mg/m2 will be IV&#xD;
      infused over 1 hour, and nab-paclitaxel at 260 mg/m2 will be IV infused over 30 minutes. For&#xD;
      L-NMMA-induced hypertension, amlodipine (10 mg) and enteric-coated low-dose aspirin (81 mg)&#xD;
      will be orally administered. Amlodipine will be administered for 6 days at each cycle,&#xD;
      starting 24 hours before the first dose of L-NMMA. Enteric-coated low-dose aspirin will be&#xD;
      administered once daily during the 6 21-day cycles. For docetaxel-induced leukopenia,&#xD;
      pegfilgrastim (6 mg) will be administered via subcutaneous injection approximately 24 hours&#xD;
      after every dose of docetaxel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">January 2021</completion_date>
  <primary_completion_date type="Actual">January 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>18 weeks</time_frame>
    <description>Primary outcome measure for Phase Ib: Assess the MTD of L-NMMA when combined with docetaxel/amlodipine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>18 weeks</time_frame>
    <description>Primary Outcome Measure for Phase II: Determine the number of participants with complete response, partial response, or stable disease after 6 cycles of L-NMMA combined with taxane chemotherapy (docetaxel, paclitaxel, or nab-paclitaxel)/amlodipine, as assessed by the RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DLTs and other adverse events</measure>
    <time_frame>18 weeks</time_frame>
    <description>Describe the DLTs and other adverse events associated with L-NMMA when combined with docetaxel/amlodipine, as assessed by the CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RP2D of the L-NMMA and docetaxel combination</measure>
    <time_frame>18 weeks</time_frame>
    <description>Determine the RP2D of the L-NMMA and docetaxel combination based on the occurrence of DLTs and MTD determination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>18 weeks</time_frame>
    <description>Assess the antitumor activity of L-NMMA when combined with taxane chemotherapy (docetaxel, paclitaxel, or nab-paclitaxel)/amlodipine, as assessed by the RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of the L-NMMA and docetaxel combination</measure>
    <time_frame>18 weeks</time_frame>
    <description>Determine the maximum plasma concentration of the L-NMMA and docetaxel combination</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration curve of the L-NMMA and docetaxel combination</measure>
    <time_frame>18 weeks</time_frame>
    <description>Determine the area under the plasma concentration curve of the L-NMMA and docetaxel combination</description>
  </other_outcome>
  <other_outcome>
    <measure>Predictive biomarkers</measure>
    <time_frame>18 weeks</time_frame>
    <description>Determine potential predictive biomarkers including serum levels of nitrate/nitrite; serum levels of inflammatory biomarkers; angiogenesis-related biomarkers; and RPL39, MLF2, and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations in cell-free DNA</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Metastatic Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 5, 7.5 (starting dose), 10, 12.5, 15, 17.5, and 20 mg/kg will be administered IV on Days 1-5. For 5-15 mg/kg L-NMMA doses, docetaxel will be administered at 75 mg/m2. For 17.5 and 20 mg/kg L-NMMA doses, docetaxel will be administered at 100 mg/m2. Docetaxel will be administered IV 15 min after the Day 1 L-NMMA infusion. Amlodipine (10 mg) will be orally administered daily for 6 days, starting 24 hours before the Day 1 L-NMMA infusion. Enteric-coated aspirin (81 mg) will be orally administered once daily during the 6 21-day cycles. Pegfilgrastim (6 mg) will be administered subcutaneously 24 h after docetaxel.&#xD;
Phase II: L-NMMA starting dose will be the RP2D determined in the Phase Ib portion of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-NMMA</intervention_name>
    <description>Nitric oxide synthase inhibitor</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>NG-monomethyl-l-arginine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Mitotic inhibitor, cytotoxic</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>TAXOTERE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Long-acting calcium channel blocker</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>besylate salt of amlodipine; NORVASC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Colony-stimulating factor</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>NEULASTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric-coated aspirin</intervention_name>
    <description>non-steroidal anti-inflammatory drug</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient must meet all of the following criteria:&#xD;
&#xD;
        • Female patients with pathologically determined advanced (progressive disease or&#xD;
        refractory to 3 cycles of standard chemotherapy) or metastatic (any line) triple negative&#xD;
        breast cancer (TNBC). TNBC is defined as: Estrogen receptor negative and progesterone&#xD;
        receptor negative (&lt;10% staining by immunohistochemistry [IHC]).&#xD;
&#xD;
        Human epidermal growth factor receptor 2 (HER2) negative. HER2 negativity must be confirmed&#xD;
        by one of the following:&#xD;
&#xD;
          -  Fluorescence in situ hybridization (FISH)-negative (FISH ratio &lt;2), or&#xD;
&#xD;
          -  IHC 0-1+, or&#xD;
&#xD;
          -  IHC 2+ AND FISH-negative (FISH ratio &lt;2). Eastern Cooperative Oncology Group&#xD;
             performance status of ≤ 2&#xD;
&#xD;
               -  Age ≥ 18 years&#xD;
&#xD;
               -  Laboratory values within the following ranges:&#xD;
&#xD;
          -  Hemoglobin ≥9.0 g/dL (transfusions permitted)&#xD;
&#xD;
          -  Absolute neutrophil count ≥1500/mm3 (1.5 x 109/L)&#xD;
&#xD;
          -  Platelet count ≥100,000/mm3 (100 x 109/L)&#xD;
&#xD;
          -  Total bilirubin &lt;2 X upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine (Cr) &lt;2 X ULN and Cr clearance (CrCl) ≥30 by Cockcroft and Gault&#xD;
&#xD;
          -  Alanine transaminase (ALT) and aspartate transaminase (AST) &lt;2 X ULN (if liver&#xD;
             metastases are present then ALT and AST must be &lt;5 X ULN)&#xD;
&#xD;
               -  Have adequate organ function (cardiac ejection fraction of ≥ 45%)&#xD;
&#xD;
               -  Negative serum pregnancy test within 7 days of the administration of the first&#xD;
                  treatment dose for women of childbearing potential (WOCBP). For WOCBP, adequate&#xD;
                  contraception must be used throughout the study.&#xD;
&#xD;
               -  Ability to understand the requirements of the study, provide written informed&#xD;
                  consent and authorization of use and disclosure of protected health information,&#xD;
                  and agree to abide by the study restrictions and return for the required&#xD;
                  assessments.&#xD;
&#xD;
               -  Patient must be willing to undergo biopsies as required by the study protocol.&#xD;
                  Biopsies will be based on acceptable clinical risks as judged by investigator.&#xD;
                  Tissue from a previous biopsy will be accepted in the form of tissue slides.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        History of poorly controlled hypertension (defined as systolic blood pressure &gt;150 mmHg at&#xD;
        baseline)&#xD;
&#xD;
          -  Patients with metastatic disease who have received radiation therapy, chemotherapy, or&#xD;
             non-cytotoxic investigational agents within 2 weeks of study treatment initiation.&#xD;
&#xD;
          -  Patients who received docetaxel at any line of treatment within the past 12 months&#xD;
&#xD;
          -  Evidence of New York Heart Association class III or greater cardiac disease&#xD;
&#xD;
          -  History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic&#xD;
             conduction abnormality within the past 12 months&#xD;
&#xD;
          -  History of congenital QT prolongation&#xD;
&#xD;
          -  Absolute corrected QT interval of &gt;480 msec in the presence of potassium &gt;4.0&#xD;
             milliequivalent/L and magnesium &gt;1.8 mg/dL&#xD;
&#xD;
          -  Any medical or psychiatric condition that would prevent informed consent or limit&#xD;
             expected survival to less than 4 weeks&#xD;
&#xD;
          -  Symptomatic central nervous system metastases&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Hypersensitivity or intolerance to L-NMMA, docetaxel, amlodipine, pegfilgrastim, or&#xD;
             their components&#xD;
&#xD;
          -  Use of amlodipine or another calcium channel blocker in the past 14 days&#xD;
&#xD;
          -  Alcoholism or hepatic disease with the exception of liver metastases&#xD;
&#xD;
          -  Severe renal insufficiency (CrCl &lt;30 mL/min [Cockcroft and Gault])&#xD;
&#xD;
          -  History of gastrointestinal bleeding, ulceration, or perforation&#xD;
&#xD;
          -  Concurrent use of potent cytochrome P450 (CYP)3A4 inhibitors&#xD;
&#xD;
          -  Concurrent use of potent CYP3A4 inducers&#xD;
&#xD;
          -  Concurrent use of medications that interact with nitrate/nitrites&#xD;
&#xD;
          -  Use of an investigational drug within 14 days preceding the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Concurrent use of any complementary or alternative medicines&#xD;
&#xD;
          -  Patients with &gt; Grade 2 neuropathy&#xD;
&#xD;
          -  Inability to take aspirin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Polly Niravath, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Houston Methodist Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2016</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital Research Institute</investigator_affiliation>
    <investigator_full_name>Polly A. Niravath, MD</investigator_full_name>
    <investigator_title>Principal Investigator, Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>nitric oxide synthase</keyword>
  <keyword>docetaxel</keyword>
  <keyword>L-NMMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>omega-N-Methylarginine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

